We would like to learn about how people who apply for healthcare financial assistance experience the application process, including things that make the application process work well or that were challenging. At this time we are not able to offer interviews to people who applied to UNC or Duke, we are interested in hearing from people who applied to other programs (such as Atrium, Novant, Wake, Vidant, ECU, Cape Fear Health Net, Physicians Reach Out, or Project Access).

Are you a young adult cancer survivor who would like to improve your health? Interested in using technology to support a healthy diet, get more physically active, and make healthy lifestyle changes? Researchers at the University of North Carolina at Chapel Hill are looking for volunteers to sign up for a 3-month research program using a Fitbit activity tracker and mobile app to improve your physical activity and dietary habits.

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Post-transplant lymphoproliferative disorder (PTLD) is the name for types of lymphoma that sometimes develop in people who have had a transplant. It can affect people who are taking medicines to suppress their immune system. This study is being done to study whether treating PTLD with a combination of the drugs tafasitamab and rituximab is more effective than rituximab alone - the current standard of care treatment for this disease.

The study is researching an experimental drug called odronextamab. The study is for patients with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma). In this study, we want to find out more about how safe and tolerable the study drug is. We will also compare how well the study drug orks compared to rituximab and chemotherapy (the current standard of care for NHL).

Have you been diagnosed with cancer or a benign disease that is being evaluated for cancer for which you may receive treatment? If so, you may be able to take part in a research study that collects biospecimens (e.g. blood, saliva, tissue, etc) and health information to better understand how cancers develop and affect the body,]. If so, you may be able to take part in a research study that aims to identify non-invasive biomarkers for cervical cancer screening and monitoring following treatment of abnormal areas on the cervix caused by HPV.

The purpose of this research study is to collect blood from patients with B-cell lymphoma who are scheduled to receive lymphodepletion chemotherapy and CAR-T cells. Research on blood samples can help in understanding how the body and cancer respond to these treatments.

This is a prospective study that will look for the kinetics of circulating tumor DNA (ctDNA) in patients with hematologic and pediatric cancer before and after undergoing standard of care treatment regimens where radiation therapy is a treatment.

Have you been diagnosed with CD30 negative peripheral T-cell lymphoma? If so, you may be able to take part in a research study that will look at the safety of adding the new study drug duvelisib, or the new study drug CC-486, to the standard chemotherapy treatment for your disease. Please contact us with questions about eligibility, or if you wish to know more.

Do you have head and neck cancer or soft tissue sarcoma? Are you planning to have surgery to remove your tumor? You may be able to participate in a research study to determine which therapies may be best for future patients. Compensation provided.